GlassScriptPhysician profile
Walaya C Methodius-Rayford
NPI 1407091499
$78,920.50
in general payments reported to CMS, 2019-2025
28 companies · $20K in 2025
The $20K reported for 2025 was more than what 94% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,799 · 2020: $370 · 2021: $394 · 2022: $558 · 2023: $35K · 2024: $19K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $58K · Travel and Lodging: $7,347 · Food and Beverage: $4,297 · Long Term Medical Supply Or Device Loan: $4,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $58,155.04 |
| Travel and Lodging | $7,347.17 |
| Food and Beverage | $4,296.50 |
| Long Term Medical Supply Or Device Loan | $4,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reprise Biomedical, INC. | $38,458.85 | 2022-2025 | Miro3d |
| Progenacare Global, LLC | $29,873.97 | 2023 | |
| Angiodynamics, INC. | $4,351.25 | 2019-2024 | Venacure 1470 Pro, Venacure 1470 Pro |
| Artivion, INC. | $3,111.01 | 2019 | |
| Boston Scientific Corporation | $1,249.96 | 2019-2025 | Varithena Administration Pack, Jetstream Sc, Opticross 35 |
| Mimedx Group, INC. | $634.84 | 2024 | |
| Janssen Pharmaceuticals, INC | $302.86 | 2019-2024 | Xarelto |
| Tela Bio, INC. | $128.41 | 2019 | |
| Acell, INC. | $122.81 | 2019 | |
| Medtronic Vascular, INC. | $122.50 | 2019 | |
| Urgo Medical North America, LLC | $72.52 | 2022 | |
| Melinta Therapeutics, LLC | $51.80 | 2021 | |
| Smith+Nephew, INC. | $51.32 | 2019-2020 | |
| Tactile Systems Technology INC | $50.36 | 2025 | Flexitouch Plus, Nimbl |
| W. L. Gore & Associates, INC. | $45.67 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $42.06 | 2019-2021 | |
| Kerecis Limited | $34.01 | 2022 | |
| Surmodics, INC. | $31.69 | 2024 | Pounce Venous Thrombectomy System, Pounce Thrombectomy |
| Bard Peripheral Vascular, INC. | $29.29 | 2022-2024 | Venovo |
| Abbott Laboratories | $24.07 | 2019 | |
| Solventum Corporation | $21.87 | 2024 | V.A.C.Ulta, V.A.C. Veraflo, Prevena |
| Cordis US Corp. | $20.73 | 2024 | Rain Sheath |
| Lilly USA, LLC | $16.67 | 2025 | Zepbound |
| Pfizer INC. | $15.31 | 2021 | |
| Osiris Therapeutics INC. | $15.03 | 2019 | |
| Organogenesis INC. | $15.01 | 2020 | |
| Reapplix INC. | $13.61 | 2022 | |
| Silk Road Medical, INC. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walaya Methodius-Rayford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.